A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients

BACKGROUND AND OBJECTIVES: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated clinical activity in a number of different cancer types. The objectives of this study were to characterize the pharmacokinetics of abemaciclib in cancer patients using population pharmacoki...

Descripción completa

Detalles Bibliográficos
Autores principales: Tate, Sonya C., Sykes, Amanda K., Kulanthaivel, Palaniappan, Chan, Edward M., Turner, P. Kellie, Cronier, Damien M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814509/
https://www.ncbi.nlm.nih.gov/pubmed/28540640
http://dx.doi.org/10.1007/s40262-017-0559-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814509/
https://www.ncbi.nlm.nih.gov/pubmed/28540640
http://dx.doi.org/10.1007/s40262-017-0559-8

Ejemplares similares